These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25905781)

  • 41. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.
    Kwak K; Jiang R; Wang JW; Jagu S; Kirnbauer R; Roden RB
    PLoS One; 2014; 9(5):e97232. PubMed ID: 24816794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and Immunogenicity.
    Chabeda A; van Zyl AR; Rybicki EP; Hitzeroth II
    Front Plant Sci; 2019; 10():779. PubMed ID: 31281327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibody.
    Wang Z; Wang D; Chen J; Gao F; Jiang Y; Yang C; Qian C; Chi X; Zhang S; Xu Y; Lu Y; Shen J; Zhang C; Li J; Zhou L; Li T; Zheng Q; Yu H; Li S; Xia N; Gu Y
    Sci Bull (Beijing); 2024 Feb; 69(4):512-525. PubMed ID: 38160175
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16.
    Chen J; Wang D; Wang Z; Wu K; Wei S; Chi X; Qian C; Xu Y; Zhou L; Li Y; Zhang S; Li T; Kong Z; Wang Y; Zheng Q; Yu H; Zhao Q; Zhang J; Xia N; Li S; Gu Y
    J Virol; 2023 Mar; 97(3):e0181922. PubMed ID: 36815785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Expression, purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli].
    Yan C; Li S; Wang J; Wei M; Huang B; Zhuang Y; Li Z; Pan H; Zhang J; Xia N
    Wei Sheng Wu Xue Bao; 2009 Nov; 49(11):1527-33. PubMed ID: 20112683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of human papillomaviruses L1 and L2 multiepitope constructs protects mice against tumor cells.
    Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
    Fundam Clin Pharmacol; 2021 Dec; 35(6):1055-1068. PubMed ID: 33930201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes.
    Heino P; Skyldberg B; Lehtinen M; Rantala I; Hagmar B; Kreider JW; Kirnbauer R; Dillner J
    J Gen Virol; 1995 May; 76 ( Pt 5)():1141-53. PubMed ID: 7537325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.
    Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies.
    Wang JW; Matsui K; Pan Y; Kwak K; Peng S; Kemp T; Pinto L; Roden RB
    Curr Protoc Microbiol; 2015 Aug; 38():14B.5.1-26. PubMed ID: 26237105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bacterial Outer Membrane Vesicles as a Platform for the Development of a Broadly Protective Human Papillomavirus Vaccine Based on the Minor Capsid Protein L2.
    Tamburini S; Zhang Y; Gagliardi A; Di Lascio G; Caproni E; Benedet M; Tomasi M; Corbellari R; Zanella I; Croia L; Grandi G; Müller M; Grandi A
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates.
    Huber B; Wang JW; Roden RBS; Kirnbauer R
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33802456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes.
    Wang XM; Cook JC; Lee JC; Jansen KU; Christensen ND; Ludmerer SW; McClements WL
    J Gen Virol; 2003 Jun; 84(Pt 6):1493-1497. PubMed ID: 12771418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers.
    Kawana K; Yasugi T; Kanda T; Kino N; Oda K; Okada S; Kawana Y; Nei T; Takada T; Toyoshima S; Tsuchiya A; Kondo K; Yoshikawa H; Tsutsumi O; Taketani Y
    Vaccine; 2003 Oct; 21(27-30):4256-60. PubMed ID: 14505907
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity.
    Zhang Y; Mariz FC; Sehr P; Spagnoli G; Koenig KM; Çelikyürekli S; Kreuziger T; Zhao X; Bolchi A; Ottonello S; Müller M
    NPJ Vaccines; 2024 Feb; 9(1):44. PubMed ID: 38402256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58.
    Brendle SA; Culp TD; Broutian TR; Christensen ND
    J Gen Virol; 2010 Jul; 91(Pt 7):1834-9. PubMed ID: 20181746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular dynamics simulation and purification of chimeric L1/L2 protein from
    Al Adawiah R; Zaenal Mustopa A; Budiarti S; Nur Umami R; Hertati A; Irawan H; Ikramullah MC; Arwansyah A; Mamangkey J; Kartikasari I; Salahudin Darusman H
    J Immunoassay Immunochem; 2024 Jul; ():1-20. PubMed ID: 38965835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18.
    Baidya S; Das R; Kabir MG; Arifuzzaman M
    Bioinformation; 2017; 13(3):86-93. PubMed ID: 28584449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protein transduction domain can enhance the humoral immunity and cross-protection of HPV16L2 peptide vaccines.
    Li L; Guo Y; Li Z; Zhou Y; Zeng YI
    Biomed Rep; 2016 Jun; 4(6):746-750. PubMed ID: 27284417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Scalable Manufacturing Approach to Single Dose Vaccination against HPV.
    Shao S; A Ortega-Rivera O; Ray S; K Pokorski J; F Steinmetz N
    Vaccines (Basel); 2021 Jan; 9(1):. PubMed ID: 33478147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.